

# Rodolfo Montironi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9066705/publications.pdf>

Version: 2024-02-01

647  
papers

25,300  
citations

7561

77  
h-index

12933

131  
g-index

663  
all docs

663  
docs citations

663  
times ranked

19999  
citing authors

#	ARTICLE	IF	CITATIONS
1	The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. American Journal of Surgical Pathology, 2013, 37, 1469-1489.	2.1	922
2	2004 WHO Classification of the Renal Tumors of the Adults. European Urology, 2006, 49, 798-805.	0.9	728
3	The International Society of Urological Pathology (ISUP) Grading System for Renal Cell Carcinoma and Other Prognostic Parameters. American Journal of Surgical Pathology, 2013, 37, 1490-1504.	2.1	639
4	p63 Is a Prostate Basal Cell Marker and Is Required for Prostate Development. American Journal of Pathology, 2000, 157, 1769-1775.	1.9	538
5	Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. European Urology, 2018, 73, 560-569.	0.9	401
6	Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical) Tj ETQqO 0 0 rgBT /Overlock 10 Tf 5	0.9	372
7	The Controversial Relationship Between Benign Prostatic Hyperplasia and Prostate Cancer: The Role of Inflammation. European Urology, 2011, 60, 106-117.	0.9	351
8	Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Modern Pathology, 2018, 31, 24-38.	2.9	324
9	Positive Surgical Margins After Radical Prostatectomy: A Systematic Review and Contemporary Update. European Urology, 2014, 65, 303-313.	0.9	319
10	The Role of Focal Therapy in the Management of Localised Prostate Cancer: A Systematic Review. European Urology, 2014, 66, 732-751.	0.9	298
11	Extended and Saturation Prostatic Biopsy in the Diagnosis and Characterisation of Prostate Cancer: A Critical Analysis of the Literature. European Urology, 2007, 52, 1309-1322.	0.9	292
12	Prognostic Factors in Prostate Cancer. Archives of Pathology and Laboratory Medicine, 2000, 124, 995-1000.	1.2	254
13	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. Modern Pathology, 2011, 24, 48-57.	2.9	239
14	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. Modern Pathology, 2011, 24, 6-15.	2.9	234
15	Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. European Urology, 2020, 77, 439-446.	0.9	228
16	Understanding the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level. European Urology, 2015, 67, 470-479.	0.9	225
17	The 2004 WHO Classification of Bladder Tumors: A Summary and Commentary. International Journal of Surgical Pathology, 2005, 13, 143-153.	0.4	220
18	Molecular pathology of lung cancer: key to personalized medicine. Modern Pathology, 2012, 25, 347-369.	2.9	215

#	ARTICLE	IF	CITATIONS
19	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. <i>Modern Pathology</i> , 2011, 24, 16-25.	2.9	214
20	2009 update on the classification of renal epithelial tumors in adults. <i>International Journal of Urology</i> , 2009, 16, 432-443.	0.5	207
21	Nonapical and Cytoplasmic Expression of Interleukin-8, CXCR1, and CXCR2 Correlates with Cell Proliferation and Microvessel Density in Prostate Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 4117-4127.	3.2	206
22	Metabolic phenotype of bladder cancer. <i>Cancer Treatment Reviews</i> , 2016, 45, 46-57.	3.4	201
23	Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. <i>Scandinavian Journal of Urology and Nephrology</i> , 2005, 39, 34-63.	1.4	194
24	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. <i>Modern Pathology</i> , 2011, 24, 26-38.	2.9	190
25	Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma. <i>Modern Pathology</i> , 2015, 28, 80-94.	2.9	190
26	Bladder cancer: translating molecular genetic insights into clinical practice. <i>Human Pathology</i> , 2011, 42, 455-481.	1.1	173
27	Staging and reporting of urothelial carcinoma of the urinary bladder. <i>Modern Pathology</i> , 2009, 22, S70-S95.	2.9	166
28	Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer. <i>European Urology</i> , 2017, 72, 632-640.	0.9	165
29	Best Practices Recommendations in the Application of Immunohistochemistry in the Prostate. <i>American Journal of Surgical Pathology</i> , 2014, 38, e6-e19.	2.1	157
30	Non-Invasive Urothelial Neoplasms: According to the Most Recent WHO Classification. <i>European Urology</i> , 2004, 46, 170-176.	0.9	155
31	Renal Tumors. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1518-1531.	2.1	154
32	Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. <i>Cancers</i> , 2021, 13, 131.	1.7	153
33	The use of morphological characteristics and texture analysis in the identification of tissue composition in prostatic neoplasia. <i>Human Pathology</i> , 2004, 35, 1121-1131.	1.1	149
34	Multilocular Cystic Renal Cell Carcinoma. <i>American Journal of Clinical Pathology</i> , 2006, 125, 217-222.	0.4	148
35	Standardization of Gleason grading among 337 European pathologists. <i>Histopathology</i> , 2013, 62, 247-256.	1.6	148
36	The World Health Organization 2016 classification of testicular non-germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. <i>Histopathology</i> , 2017, 70, 513-521.	1.6	143

#	ARTICLE	IF	CITATIONS
37	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 461-493.	1.2	143
38	Evidence for Common Clonal Origin of Multifocal Lung Cancers. <i>Journal of the National Cancer Institute</i> , 2009, 101, 560-570.	3.0	142
39	A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. <i>Nature Genetics</i> , 2013, 45, 747-755.	9.4	138
40	ERG and TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. <i>Modern Pathology</i> , 2011, 24, 1120-1127.	2.9	130
41	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. <i>Modern Pathology</i> , 2011, 24, 39-47.	2.9	127
42	Interobserver Variability Between Expert Urologic Pathologists for Extraprostatic Extension and Surgical Margin Status in Radical Prostatectomy Specimens. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1503-1512.	2.1	123
43	Variants and new entities of bladder cancer. <i>Histopathology</i> , 2019, 74, 77-96.	1.6	120
44	Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies. <i>BJU International</i> , 2005, 95, 1146-1152.	1.3	118
45	Handling and Staging of Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1505-1517.	2.1	118
46	Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. <i>Prostate</i> , 2000, 45, 72-79.	1.2	117
47	The Critical Role of the Pathologist in Determining Eligibility for Active Surveillance as a Management Option in Patients With Prostate Cancer: Consensus Statement With Recommendations Supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 1387-1405.	1.2	117
48	Staging of bladder cancer. <i>Histopathology</i> , 2019, 74, 112-134.	1.6	117
49	Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. <i>Scandinavian Journal of Urology and Nephrology</i> , 2005, 39, 20-33.	1.4	114
50	Staging of prostate cancer. <i>Histopathology</i> , 2012, 60, 87-117.	1.6	114
51	Sarcomatoid Carcinoma of the Urinary Bladder. <i>American Journal of Surgical Pathology</i> , 2011, 35, e34-e46.	2.1	112
52	Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1757-1768.	2.0	110
53	Handling and Pathology Reporting of Specimens with Carcinoma of the Urinary Bladder, Ureter, and Renal Pelvis. <i>European Urology</i> , 2004, 45, 257-266.	0.9	108
54	Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. <i>Human Pathology</i> , 2009, 40, 10-29.	1.1	108

#	ARTICLE	IF	CITATIONS
55	ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology. <i>European Urology</i> , 2013, 63, 16-35.	0.9	107
56	Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. <i>Modern Pathology</i> , 2015, 28, 612-630.	2.9	106
57	Plasmacytoid urothelial carcinoma of the bladder. <i>Human Pathology</i> , 2009, 40, 1023-1028.	1.1	103
58	A Contemporary Update on Pathology Standards for Bladder Cancer: Transurethral Resection and Radical Cystectomy Specimens. <i>European Urology</i> , 2013, 63, 321-332.	0.9	103
59	Epigenetic modulations and lineage plasticity in advanced prostate cancer. <i>Annals of Oncology</i> , 2020, 31, 470-479.	0.6	103
60	Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002, 440, 3-11.	1.4	102
61	Lymphoepithelioma-like carcinoma of the urinary bladder: a clinicopathologic study of 13 cases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2001, 438, 552-557.	1.4	101
62	Multilocular cystic renal cell carcinoma is a subtype of clear cell renal cell carcinoma. <i>Modern Pathology</i> , 2010, 23, 931-936.	2.9	101
63	Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications. <i>Cells</i> , 2020, 9, 2653.	1.8	98
64	Optimizing Performance and Interpretation of Prostate Biopsy: A Critical Analysis of the Literature. <i>European Urology</i> , 2010, 58, 851-864.	0.9	96
65	Contemporary Grading for Prostate Cancer: Implications for Patient Care. <i>European Urology</i> , 2013, 63, 892-901.	0.9	95
66	Neuroendocrine tumours of the urinary system and male genital organs: clinical significance. <i>BJU International</i> , 2009, 103, 1464-1470.	1.3	94
67	The plasmacytoid carcinoma of the bladder – rare variant of aggressive urothelial carcinoma. <i>International Journal of Cancer</i> , 2011, 129, 346-354.	2.3	94
68	Collecting Duct Carcinoma Versus Renal Medullary Carcinoma. <i>American Journal of Surgical Pathology</i> , 2014, 38, 871-874.	2.1	90
69	Consensus on molecular imaging and theranostics in prostate cancer. <i>Lancet Oncology</i> , The, 2018, 19, e696-e708.	5.1	90
70	Lymphoepithelioma-like Carcinoma of the Urinary Bladder. <i>American Journal of Surgical Pathology</i> , 2011, 35, 474-483.	2.1	88
71	Biomarkers in bladder cancer: Translational and clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 73-111.	2.0	88
72	Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. <i>Human Pathology</i> , 2010, 41, 155-162.	1.1	86

#	ARTICLE	IF	CITATIONS
73	A Contemporary Update on Pathology Reporting for Prostate Cancer: Biopsy and Radical Prostatectomy Specimens. <i>European Urology</i> , 2012, 62, 20-39.	0.9	85
74	Clear Cell-Papillary Renal Cell Carcinoma of the Kidney Not Associated With End-stage Renal Disease. <i>American Journal of Surgical Pathology</i> , 2015, 39, 873-888.	2.1	83
75	Evaluating radical prostatectomy specimens: Therapeutic and prognostic importance. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1997, 430, 1-16.	1.4	82
76	Urothelial Carcinoma With an Inverted Growth Pattern Can be Distinguished From Inverted Papilloma by Fluorescence In Situ Hybridization, Immunohistochemistry, and Morphologic Analysis. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1861-1867.	2.1	82
77	Cleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. <i>Histopathology</i> , 2016, 69, 441-449.	1.6	82
78	Multilocular cystic renal cell carcinoma : a report of 45 cases of a kidney tumor of low malignant potential. <i>American Journal of Clinical Pathology</i> , 2006, 125, 217-22.	0.4	81
79	Soft tissue tumors of the urinary bladder. <i>Human Pathology</i> , 2007, 38, 963-977.	1.1	79
80	Natural history of urothelial inverted papilloma. <i>Cancer</i> , 2006, 107, 2622-2627.	2.0	78
81	Current Pathology Keys of Renal Cell Carcinoma. <i>European Urology</i> , 2011, 60, 634-643.	0.9	78
82	<i>BAP1</i> , <i>PBRM1</i> and <i>SETD2</i> in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1201-1210.	1.5	78
83	AUTOMATED LOCATION OF DYSPLASTIC FIELDS IN COLORECTAL HISTOLOGY USING IMAGE TEXTURE ANALYSIS. , 1997, 182, 68-75.		77
84	Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 111-117.	1.6	77
85	PD-L1 assessment in urothelial carcinoma: a practical approach. <i>Annals of Translational Medicine</i> , 2019, 7, 690-690.	0.7	77
86	Handling and Pathology Reporting of Prostate Biopsies*1. <i>European Urology</i> , 2004, 46, 177-181.	0.9	76
87	Immune checkpoint inhibitors for metastatic bladder cancer. <i>Cancer Treatment Reviews</i> , 2018, 64, 11-20.	3.4	76
88	Mechanisms of Disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate. <i>Nature Reviews Urology</i> , 2007, 4, 321-332.	1.4	75
89	Multilocular Cystic Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1425-1433.	2.1	75
90	Invasive micropapillary urothelial carcinoma of the bladder. <i>Human Pathology</i> , 2010, 41, 1159-1164.	1.1	73

#	ARTICLE	IF	CITATIONS
91	p16 expression is not associated with human papillomavirus in urinary bladder squamous cell carcinoma. <i>Modern Pathology</i> , 2012, 25, 1526-1533.	2.9	73
92	Malignant Perivascular Epithelioid Cell Neoplasm (PEComa) of the Urinary Bladder With TFE3 Gene Rearrangement. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1619-1626.	2.1	73
93	The origins of urothelial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 865-880.	1.1	72
94	Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. <i>Annals of Surgical Oncology</i> , 2015, 22, 2094-2100.	0.7	72
95	Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. <i>Cancers</i> , 2020, 12, 1449.	1.7	72
96	Metabolic alterations in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2015, 41, 767-776.	3.4	71
97	Handling and Pathology Reporting of Radical Prostatectomy Specimens. <i>European Urology</i> , 2003, 44, 626-636.	0.9	70
98	Atypical Foci Suspicious but not Diagnostic of Malignancy in Prostate Needle Biopsies. <i>European Urology</i> , 2006, 50, 666-674.	0.9	69
99	The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens. <i>Human Pathology</i> , 2007, 38, 1207-1211.	1.1	69
100	Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 465, 199-205.	1.4	69
101	Advances in Renal Neoplasia. <i>Urology</i> , 2014, 83, 969-974.	0.5	67
102	Serous borderline tumors of the ovary. A clinicopathologic, immunohistochemical, and quantitative study of 44 cases. <i>Cancer</i> , 1992, 70, 152-160.	2.0	65
103	Cystic Nephroma and Mixed Epithelial and Stromal Tumour of the Kidney: Opposite Ends of the Spectrum of the Same Entity?. <i>European Urology</i> , 2008, 54, 1237-1246.	0.9	65
104	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 10.	3.5	65
105	Pathology and Genetics: Tumours of the Urinary System and Male Genital System. <i>European Urology</i> , 2016, 70, 120-123.	0.9	65
106	Is There a Role for Immunotherapy in Prostate Cancer?. <i>Cells</i> , 2020, 9, 2051.	1.8	65
107	Squamous differentiation in primary urothelial carcinoma of the urinary tract as seen by MAC387 immunohistochemistry. <i>Journal of Clinical Pathology</i> , 2006, 60, 332-335.	1.0	64
108	Telomere Shortening and Chromosomal Abnormalities in Intestinal Metaplasia of the Urinary Bladder. <i>Clinical Cancer Research</i> , 2007, 13, 6232-6236.	3.2	64

#	ARTICLE	IF	CITATIONS
109	Cystic Lesions of the Prostate Gland: An Ultrasound Classification With Pathological Correlation. <i>Journal of Urology</i> , 2009, 181, 647-657.	0.2	64
110	Emerging concepts on drug resistance in bladder cancer: Implications for future strategies. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 81-90.	2.0	64
111	Prostate cancer heterogeneity: Discovering novel molecular targets for therapy. <i>Cancer Treatment Reviews</i> , 2017, 54, 68-73.	3.4	64
112	Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials. <i>European Urology Focus</i> , 2022, 8, 514-521.	1.6	64
113	Incidentally detected prostate cancer in cystoprostatectomies: pathological and morphometric comparison with clinically detected cancer in totally embedded specimens. <i>Human Pathology</i> , 2005, 36, 646-654.	1.1	63
114	Laser-assisted Microdissection in Translational Research. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2013, 21, 31-47.	0.6	63
115	Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification. <i>Endocrine Pathology</i> , 2016, 27, 123-135.	5.2	63
116	Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. <i>Drugs in Context</i> , 2018, 7, 1-8.	1.0	63
117	Surveillance after prostate focal therapy. <i>World Journal of Urology</i> , 2019, 37, 397-407.	1.2	63
118	Urothelial Carcinoma of the Bladder, Lipid Cell Variant: Clinicopathologic Findings and LOH Analysis. <i>American Journal of Surgical Pathology</i> , 2010, 34, 371-376.	2.1	62
119	Ureteral endometriosis: clinicopathological and immunohistochemical study of 7 cases. <i>Human Pathology</i> , 2008, 39, 954-959.	1.1	59
120	Glandular lesions of the urinary bladder: clinical significance and differential diagnosis. <i>Histopathology</i> , 2011, 58, 811-834.	1.6	59
121	The reasons behind variation in Gleason grading of prostatic biopsies: areas of agreement and misconception among 266 European pathologists. <i>Histopathology</i> , 2014, 64, 405-411.	1.6	59
122	<i>Ex vivo</i> fluorescence confocal microscopy: the first application for real-time pathological examination of prostatic tissue. <i>BJU International</i> , 2019, 124, 469-476.	1.3	59
123	Implications of the International Society of Urological Pathology Modified Gleason Grading System. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 426-434.	1.2	58
124	Role of STAT3 pathway in genitourinary tumors. <i>Future Science OA</i> , 2015, 1, FSO15.	0.9	58
125	Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 41-47.	0.2	58
126	Upregulation of Tissue and Urinary Nicotinamide N-Methyltransferase in Bladder Cancer: Potential for the Development of a Urine-Based Diagnostic Test. <i>Cell Biochemistry and Biophysics</i> , 2013, 65, 473-483.	0.9	56

#	ARTICLE	IF	CITATIONS
127	Current practice of Gleason grading of prostate carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 448, 111-118.	1.4	55
128	Is Incidentally Detected Prostate Cancer in Patients Undergoing Radical Cystoprostatectomy Clinically Significant?. <i>American Journal of Clinical Pathology</i> , 2009, 131, 279-283.	0.4	55
129	Low-risk Prostate Cancer: Identification, Management, and Outcomes. <i>European Urology</i> , 2017, 72, 238-249.	0.9	55
130	Precancerous Lesions and Conditions of the Prostate. <i>Annals of the New York Academy of Sciences</i> , 2002, 963, 169-184.	1.8	54
131	Telomerase reverse transcriptase (<scp>TERT</scp>) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change. <i>Histopathology</i> , 2016, 69, 107-113.	1.6	54
132	Morphological classification and definition of benign, preneoplastic and noninvasive neoplastic lesions of the urinary bladder. <i>Histopathology</i> , 2008, 53, 621-633.	1.6	53
133	Quantitative tissue analyses of prostate cancer foci in an unselected cystoprostatectomy series. <i>BJU International</i> , 2012, 110, 517-523.	1.3	53
134	Metanephric adenoma: the utility of immunohistochemical and cytogenetic analyses in differential diagnosis, including solid variant papillary renal cell carcinoma and epithelial-predominant nephroblastoma. <i>Modern Pathology</i> , 2015, 28, 1236-1248.	2.9	53
135	New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen. <i>Frontiers in Oncology</i> , 2018, 8, 653.	1.3	53
136	Analysis of the Capillary Architecture in the Precursors of Prostate Cancer: Recent Findings and New Concepts. <i>European Urology</i> , 1996, 30, 191-200.	0.9	52
137	Microcystic urothelial carcinoma: morphology, immunohistochemistry and clinical behaviour. <i>Histopathology</i> , 2014, 64, 872-879.	1.6	52
138	Intermediate-risk Prostate Cancer: Stratification and Management. <i>European Urology Oncology</i> , 2020, 3, 270-280.	2.6	51
139	Pleomorphic giant cell carcinoma of the urinary bladder. <i>Human Pathology</i> , 2009, 40, 1461-1466.	1.1	50
140	Prostatic intraepithelial neoplasia: its morphological and molecular diagnosis and clinical significance. <i>BJU International</i> , 2011, 108, 1394-1401.	1.3	49
141	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. <i>Targeted Oncology</i> , 2015, 10, 517-522.	1.7	49
142	AR-V7 and prostate cancer: The watershed for treatment selection?. <i>Cancer Treatment Reviews</i> , 2016, 43, 27-35.	3.4	49
143	FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations. <i>Modern Pathology</i> , 2009, 22, 627-632.	2.9	47
144	Not all gleason pattern 4 prostate cancers are created equal: A study of latent prostatic carcinomas in a cystoprostatectomy and autopsy series. <i>Prostate</i> , 2015, 75, 1277-1284.	1.2	47

#	ARTICLE	IF	CITATIONS
145	Immune checkpoint inhibitors and prostate cancer: a new frontier?. <i>Oncology Reviews</i> , 2016, 10, 293.	0.8	47
146	Challenges in Pathologic Staging of Bladder Cancer: Proposals for Fresh Approaches of Assessing Pathologic Stage in Light of Recent Studies and Observations Pertaining to Bladder Histoanatomic Variances. <i>Advances in Anatomic Pathology</i> , 2017, 24, 113-127.	2.4	47
147	Workgroup 1: Origins of prostate cancer. , 1996, 78, 362-365.		46
148	The prospect of precision therapy for renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2016, 49, 37-44.	3.4	46
149	HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer. <i>Human Pathology</i> , 2006, 37, 1137-1144.	1.1	45
150	Molecular determinants of tumor recurrence in the urinary bladder. <i>Future Oncology</i> , 2009, 5, 843-857.	1.1	45
151	Overexpression of ELAV-like Protein HuR is Associated with Increased COX-2 Expression in Atrophy, High-grade Prostatic Intraepithelial Neoplasia, and Incidental Prostate Cancer in Cystoprostatectomies. <i>European Urology</i> , 2009, 56, 105-112.	0.9	45
152	Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry. <i>Human Pathology</i> , 2013, 44, 2227-2233.	1.1	45
153	Evidence for Polyclonal Origin of Multifocal Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 8087-8093.	3.2	43
154	Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 809-824.	1.9	43
155	Histopathological findings after treatment of prostate cancer using high-intensity focused ultrasound (HIFU). <i>Prostate</i> , 2010, 70, 1196-1200.	1.2	42
156	Urothelial lesions with inverted growth patterns: histogenesis, molecular genetic findings, differential diagnosis and clinical management. <i>BJU International</i> , 2011, 107, 532-537.	1.3	42
157	Prognostic and predictive factors in prostate cancer: Historical perspectives and recent international consensus initiatives. <i>Scandinavian Journal of Urology and Nephrology</i> , 2005, 39, 8-19.	1.4	41
158	Search for residual prostate cancer on pT0 radical prostatectomy after positive biopsy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007, 450, 371-378.	1.4	41
159	Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur. <i>Cancer</i> , 2008, 112, 636-644.	2.0	41
160	International Society of Urological Pathology (ISUP) Consensus Conference on Renal Neoplasia. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1463-1468.	2.1	41
161	Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 465, 623-628.	1.4	41
162	Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists. <i>Annals of Diagnostic Pathology</i> , 2014, 18, 333-342.	0.6	41

#	ARTICLE	IF	CITATIONS
163	Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists. <i>Histopathology</i> , 2015, 67, 313-324.	1.6	41
164	Re: Gut Microbiome Influences Efficacy of PD-1-based Immunotherapy Against Epithelial Tumors. <i>European Urology</i> , 2018, 74, 521-522.	0.9	41
165	Diagnosis of Prostatic Intraepithelial Neoplasia: Prostate Working Group 1 Consensus Report. <i>Scandinavian Journal of Urology and Nephrology</i> , 2000, 34, 3-10.	1.4	40
166	Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists. <i>Histopathology</i> , 2014, 65, 216-227.	1.6	40
167	The Identification of Immunological Biomarkers in Kidney Cancers. <i>Frontiers in Oncology</i> , 2018, 8, 456.	1.3	40
168	Morphological assessment of radical prostatectomy specimens. A protocol with clinical relevance. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2003, 442, 211-217.	1.4	39
169	Flat urothelial carcinoma in situ of the bladder with glandular differentiation. <i>Human Pathology</i> , 2011, 42, 1653-1659.	1.1	38
170	Neuroendocrine differentiation in prostate cancer: Novel morphological insights and future therapeutic perspectives. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 630-637.	3.3	38
171	Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 445-455.	1.4	38
172	The Human Microbiota and Prostate Cancer: Friend or Foe?. <i>Cancers</i> , 2019, 11, 459.	1.7	38
173	Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. <i>Cells</i> , 2019, 8, 43.	1.8	38
174	Treating Prostate Cancer by Antibody-Drug Conjugates. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1551.	1.8	38
175	Nuclear changes in the normal-looking columnar epithelium adjacent to and distant from prostatic intraepithelial neoplasia and prostate cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2000, 437, 625-634.	1.4	37
176	Prostate carcinoma II: prognostic factors in prostate needle biopsies. <i>BJU International</i> , 2006, 97, 492-497.	1.3	37
177	Impact of Prostate Cancer Multifocality on Its Biology and Treatment. <i>Journal of Endourology</i> , 2010, 24, 799-804.	1.1	37
178	Ex vivo fluorescence confocal microscopy: prostatic and periprostatic tissues atlas and evaluation of the learning curve. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 511-520.	1.4	37
179	Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate. <i>Modern Pathology</i> , 2007, 20, 175-182.	2.9	36
180	Intratubular Germ Cell Neoplasia of the Testis:. <i>European Urology</i> , 2002, 41, 651-654.	0.9	35

#	ARTICLE	IF	CITATIONS
181	An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heatmaps. <i>Histopathology</i> , 2013, 63, 756-766.	1.6	35
182	TERT Promoter Mutations Occur Frequently in Urothelial Papilloma and Papillary Urothelial Neoplasm of Low Malignant Potential. <i>European Urology</i> , 2017, 71, 497-498.	0.9	35
183	Understanding the molecular genetics of renal cell neoplasia: implications for diagnosis, prognosis and therapy. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 843-864.	1.1	34
184	Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression and overexpression of EGFR. <i>Human Pathology</i> , 2015, 46, 805-812.	1.1	34
185	Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer. <i>Cells</i> , 2020, 9, 1073.	1.8	34
186	Towards a new WHO classification of renal cell tumor: what the clinician needs to know—a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 1506-1520.	0.6	34
187	Hypermethylation of tumor-suppressor gene CpG islands in small-cell carcinoma of the urinary bladder. <i>Modern Pathology</i> , 2008, 21, 355-362.	2.9	33
188	Small cell carcinoma of the urinary bladder. <i>Histology and Histopathology</i> , 2010, 25, 217-21.	0.5	33
189	Contemporary Gleason grading and novel Grade Groups in clinical practice. <i>Current Opinion in Urology</i> , 2016, 26, 488-492.	0.9	32
190	Tubulocystic renal cell carcinoma is an entity that is immunohistochemically and genetically distinct from papillary renal cell carcinoma. <i>Histopathology</i> , 2016, 68, 850-857.	1.6	32
191	Mixed Epithelial and Stromal Tumors of the Kidney. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1114-1122.	2.1	31
192	Handling and reporting of transurethral resection specimens of the bladder in Europe: a web-based survey by the European Network of Uro-pathology (ENUP). <i>Histopathology</i> , 2011, 58, 579-585.	1.6	31
193	Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate. <i>American Journal of Surgical Pathology</i> , 2020, 44, 673-680.	2.1	31
194	Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice. <i>Current Drug Metabolism</i> , 2017, 18, 712-722.	0.7	31
195	The origin of prostate metastases: emerging insights. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 765-773.	2.7	30
196	Data representation and reduction for chromatin texture in nuclei from premalignant prostatic, esophageal, and colonic lesions. <i>Cytometry</i> , 2000, 41, 133-138.	1.8	29
197	Subvisual changes in chromatin organization state are detected by karyometry in the histologically normal urothelium in patients with synchronous papillary carcinoma1 The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the University of Ancona or the National Cancer Institute.. <i>Human Pathology</i> , 2003, 34, 893-901.	1.1	29
198	Urothelial and incidental prostate carcinoma in prostates from cystoprostatectomies for bladder cancer: is there a relationship between urothelial and prostate cancer?. <i>BJU International</i> , 2009, 103, 1058-1063.	1.3	29

#	ARTICLE	IF	CITATIONS
199	Intraductal carcinoma of the prostate: Precursor or aggressive phenotype of prostate cancer?. Prostate, 2013, 73, 442-448.	1.2	29
200	Cystic partially regressed clear cell renal cell carcinoma: a potential mimic of multilocular cystic renal cell carcinoma. Histopathology, 2013, 63, 767-779.	1.6	29
201	Loss of nuclear BAP1 protein expression is a marker of poor prognosis in patients with clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 338.e11-338.e18.	0.8	29
202	Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. Cancers, 2019, 11, 830.	1.7	29
203	Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg. BJU International, 2006, 98, 54-58.	1.3	28
204	Increased androgen receptor gene copy number is associated with <i>TMPRSS2-ERG</i> rearrangement in prostatic small cell carcinoma. Molecular Carcinogenesis, 2015, 54, 900-907.	1.3	28
205	Tp53 and its potential therapeutic role as a target in bladder cancer. Expert Opinion on Therapeutic Targets, 2017, 21, 401-414.	1.5	28
206	RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications. Journal of Clinical Pathology, 2019, 72, 135-139.	1.0	28
207	Digital Frozen Sections with Fluorescence Confocal Microscopy During Robot-assisted Radical Prostatectomy: Surgical Technique. European Urology, 2021, 80, 724-729.	0.9	28
208	Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma. Oncotarget, 2015, 6, 32161-32168.	0.8	28
209	Oncotargets in Different Renal Cancer Subtypes. Current Drug Targets, 2015, 16, 125-135.	1.0	28
210	Critical Evaluation of the Prostate from Cystoprostatectomies for Bladder Cancer: Insights from a Complete Sampling with the Whole Mount Technique. European Urology, 2009, 55, 1305-1309.	0.9	27
211	Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. Cancer and Metastasis Reviews, 2014, 33, 321-331.	2.7	27
212	Biomarkers in renal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 359-365.	1.4	27
213	Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. Cancer Treatment Reviews, 2018, 68, 80-85.	3.4	27
214	Features and Prognostic Significance of Intraductal Carcinoma of the Prostate. European Urology Oncology, 2018, 1, 21-28.	2.6	27
215	Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art. Cancers, 2021, 13, 546.	1.7	27
216	Prostate carcinoma I: prognostic factors in radical prostatectomy specimens and pelvic lymph nodes. BJU International, 2006, 97, 485-491.	1.3	26

#	ARTICLE	IF	CITATIONS
217	Immunohistochemical Expression of Endothelin-1 and Endothelin-A and Endothelin-B Receptors in High-Grade Prostatic Intraepithelial Neoplasia and Prostate Cancer. <i>European Urology</i> , 2007, 52, 1682-1690.	0.9	26
218	Large cell undifferentiated carcinoma of the urinary bladder. <i>Pathology</i> , 2010, 42, 364-368.	0.3	26
219	Do Not Misinterpret Intraductal Carcinoma of the Prostate as High-grade Prostatic Intraepithelial Neoplasia!. <i>European Urology</i> , 2012, 62, 518-522.	0.9	26
220	Adult primary paratesticular mesenchymal tumors with emphasis on a case presentation and discussion of spermatic cord leiomyosarcoma. <i>Diagnostic Pathology</i> , 2014, 9, 90.	0.9	26
221	Prostate cancer: from Gleason scoring to prognostic grade grouping. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 433-440.	1.1	26
222	Pros-IT CNR: an Italian prostate cancer monitoring project. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 165-172.	1.4	26
223	Clinical performance and utility of a NNMT-based urine test for bladder cancer. <i>International Journal of Biological Markers</i> , 2018, 33, 94-101.	0.7	26
224	Is Extraprostatic Extension of Cancer Predictable? A Review of Predictive Tools and an External Validation Based on a Large and a Single Center Cohort of Prostate Cancer Patients. <i>Urology</i> , 2019, 129, 8-20.	0.5	26
225	Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution. <i>Clinical Drug Investigation</i> , 2019, 39, 503-519.	1.1	26
226	The Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implications. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5683.	1.8	26
227	Molecular Foundations for Personalized Therapy in Prostate Cancer. <i>Current Drug Targets</i> , 2015, 16, 103-114.	1.0	26
228	Androgen-Deprived Prostate Adenocarcinoma: Evaluation of Treatment-Related Changes versus No Distinctive Treatment Effect with a Bayesian Belief Network. <i>European Urology</i> , 1996, 30, 307-315.	0.9	25
229	Î±-Methylacyl Coenzyme A Racemase, Ki-67, and Topoisomerase IIÎ± in Cystoprostatectomies With Incidental Prostate Cancer. <i>American Journal of Clinical Pathology</i> , 2007, 128, 657-664.	0.4	25
230	Lymphoepithelioma-like carcinoma of the prostate. <i>Human Pathology</i> , 2009, 40, 982-987.	1.1	25
231	Is atypical adenomatous hyperplasia of the prostate a precursor lesion?. <i>Prostate</i> , 2011, 71, 1746-1751.	1.2	25
232	Iatrogenic changes in the urinary tract. <i>Histopathology</i> , 2017, 70, 10-25.	1.6	25
233	Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma. <i>European Urology Focus</i> , 2018, 4, 880-888.	1.6	25
234	Digital pathology and COVID-19 and future crises: pathologists can safely diagnose cases from home using a consumer monitor and a mini PC. <i>Journal of Clinical Pathology</i> , 2020, 73, 695-696.	1.0	25

#	ARTICLE	IF	CITATIONS
235	Neoplasms of the urinary bladder. , 2008, , 258-351.		25
236	Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives. Current Drug Metabolism, 2017, 18, 700-711.	0.7	25
237	Prostatic intraepithelial neoplasia (PIN). Performance of bayesian belief network for diagnosis and grading. Journal of Pathology, 1995, 177, 153-162.	2.1	24
238	Precursors of Prostatic Cancer: Progression, Regression and Chemoprevention. European Urology, 1996, 30, 133-137.	0.9	24
239	Subtle changes in benign tissue adjacent to prostate neoplasia detected with a Bayesian belief network. , 1997, 182, 442-449.		24
240	Morphometric index of adult renal cell carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2000, 437, 82-89.	1.4	24
241	Solitary Fibrous Tumour of the Prostate Identified on Needle Biopsy. European Urology, 2009, 56, 564-567.	0.9	24
242	Suppression of <i>CHK1</i> by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. Cancer Discovery, 2015, 5, 550-563.	7.7	24
243	T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-II ± , survivin, and E-cadherin. Human Pathology, 2016, 57, 78-84.	1.1	24
244	The Morphologic Spectrum of Sertoliform Cystadenoma of the Rete Testis. American Journal of Surgical Pathology, 2018, 42, 141-149.	2.1	24
245	Exploring Small Extracellular Vesicles for Precision Medicine in Prostate Cancer. Frontiers in Oncology, 2018, 8, 221.	1.3	24
246	Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study. Health and Quality of Life Outcomes, 2018, 16, 122.	1.0	24
247	Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers. Expert Review of Molecular Diagnostics, 2020, 20, 231-243.	1.5	24
248	Digital Biopsy with Fluorescence Confocal Microscope for Effective Real-time Diagnosis of Prostate Cancer: A Prospective, Comparative Study. European Urology Oncology, 2021, 4, 784-791.	2.6	24
249	Clinicopathologic analysis of upper urinary tract carcinoma with variant histology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 111-120.	1.4	24
250	Molecular pathology of urothelial carcinoma. Human Pathology, 2021, 113, 67-83.	1.1	24
251	Joint Appraisal of the Radical Prostatectomy Specimen by the Urologist and the Uropathologist: Together, We Can Do It Better. European Urology, 2009, 56, 951-955.	0.9	23
252	Inverted (Endophytic) Noninvasive Lesions and Neoplasms of the Urothelium: The Cinderella Group Has Yet to Be Fully Exploited. European Urology, 2011, 59, 225-230.	0.9	23

#	ARTICLE	IF	CITATIONS
253	<i>KRAS</i> mutation is present in a small subset of primary urinary bladder adenocarcinomas. <i>Histopathology</i> , 2012, 61, 1036-1042.	1.6	23
254	Central Prostate Pathology Review: Should It Be Mandatory?. <i>European Urology</i> , 2013, 64, 199-201.	0.9	23
255	Immunoglobulin G4-related Disease in Genitourinary Organs: An Emerging Fibroinflammatory Entity Often Misdiagnosed Preoperatively as Cancer. <i>European Urology</i> , 2013, 64, 865-872.	0.9	23
256	FGFR3 and Cyclin D3 as urine biomarkers of bladder cancer recurrence. <i>Biomarkers in Medicine</i> , 2016, 10, 243-253.	0.6	23
257	Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy. <i>Cancers</i> , 2019, 11, 196.	1.7	23
258	Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e84-e91.	0.9	23
259	Pathology of the prostate in radical cystectomy specimens: A critical review. <i>Surgical Oncology</i> , 2009, 18, 73-84.	0.8	22
260	Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy. <i>Prostate</i> , 2012, 72, 108-115.	1.2	22
261	Human Papillomavirus is Not an Etiologic Agent of Urothelial Inverted Papillomas. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1223-1228.	2.1	22
262	Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy. <i>BioDrugs</i> , 2016, 30, 263-273.	2.2	22
263	<i>TERT</i> promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract. <i>Future Oncology</i> , 2017, 13, 705-714.	1.1	22
264	Lymphoepithelioma-like carcinoma of the upper urinary tract. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 703-709.	1.4	22
265	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2020, 12, 84.	1.7	22
266	Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation. <i>Oncotarget</i> , 2017, 8, 54096-54105.	0.8	22
267	Atypical adenomatous hyperplasia (adenosis) of the prostate: Development of a bayesian belief network for its distinction from well-differentiated adenocarcinoma. <i>Human Pathology</i> , 1996, 27, 396-407.	1.1	21
268	2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections. <i>European Urology Supplements</i> , 2009, 8, 453-457.	0.1	21
269	Atypical Adenomatous Hyperplasia of Prostate Lacks TMPRSS2-ERG Gene Fusion. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1550-1554.	2.1	21
270	Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing. <i>Cancers</i> , 2021, 13, 1424.	1.7	21

#	ARTICLE	IF	CITATIONS
271	COMPUTERIZED SCENE SEGMENTATION FOR THE DISCRIMINATION OF ARCHITECTURAL FEATURES IN DUCTAL PROLIFERATIVE LESIONS OF THE BREAST. , 1997, 181, 374-380.		20
272	Subtle Morphological and Molecular Changes in Normal-Looking Epithelium in Prostates with Prostatic Intraepithelial Neoplasia or Cancer. European Urology, 1999, 35, 468-473.	0.9	20
273	Carcinoma of the prostate: inherited susceptibility, somatic gene defects and androgen receptors. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 444, 503-8.	1.4	20
274	Atypical Adenomatous Hyperplasia (Adenosis) of the Prostate: DNA Ploidy Analysis and Immunophenotype. International Journal of Surgical Pathology, 2005, 13, 167-173.	0.4	20
275	Histopathology reporting of prostate needle biopsies. 2005 update. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 1-13.	1.4	20
276	Telomere shortening distinguishes inverted urothelial neoplasms. Histopathology, 2013, 62, 595-601.	1.6	20
277	Clear Cell Renal Cell Carcinoma (ccRCC) with Hemangioblastoma-like Features: A Previously Unreported Pattern of ccRCC with Possible Clinical Significance. European Urology, 2014, 66, 806-810.	0.9	20
278	Emerging Immunotargets in Metastatic Renal Cell Carcinoma. Current Drug Targets, 2016, 17, 771-776.	1.0	20
279	Solitary fibrous tumour of the genitourinary tract: a clinicopathological study of 11 cases and their association with the <i>NAB2</i> - <i>STAT6</i> fusion gene. Journal of Clinical Pathology, 2017, 70, 508-514.	1.0	20
280	Long Non-coding RNAs in Prostate Cancer with Emphasis on Second Chromosome Locus Associated with Prostate-1 Expression. Frontiers in Oncology, 2017, 7, 305.	1.3	20
281	Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. Frontiers in Oncology, 2018, 8, 397.	1.3	20
282	Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. Expert Review of Molecular Diagnostics, 2018, 18, 645-655.	1.5	20
283	BAP1 in solid tumors. Future Oncology, 2019, 15, 2151-2162.	1.1	20
284	Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer. Apms, 2019, 127, 545-553.	0.9	20
285	Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future Challenges. Frontiers in Oncology, 2019, 9, 228.	1.3	20
286	Microbiome and Cancers, With Focus on Genitourinary Tumors. Frontiers in Oncology, 2019, 9, 178.	1.3	20
287	Impact of Surgical Approach on Patient-Reported Outcomes after Radical Prostatectomy: A Propensity Score-Weighted Analysis from a Multicenter, Prospective, Observational Study (The Pros-IT CNR) Tj ETQq1 1 0.784314 rgBT / Overlock	1.4	20
288	Real-time assessment of surgical margins during radical prostatectomy: a novel approach that uses fluorescence confocal microscopy for the evaluation of peri-prostatic soft tissue. BJU International, 2020, 125, 487-489.	1.3	20

#	ARTICLE	IF	CITATIONS
289	Molecular characteristics of urothelial neoplasms in children and young adults: a subset of tumors from young patients harbors chromosomal abnormalities but not FGFR3 or TP53 gene mutations. <i>Modern Pathology</i> , 2014, 27, 1540-1548.	2.9	19
290	Seminal Vesicle Intraepithelial Neoplasia Versus Basal Cell Hyperplasia in a Seminal Vesicle. <i>European Urology</i> , 2014, 66, 623-627.	0.9	19
291	Inflammatory myofibroblastic tumour of the urinary bladder: the role of immunoglobulin G4 and the comparison of two immunohistochemical antibodies and fluorescence <i>in situ</i> hybridization for the detection of anaplastic lymphoma kinase alterations. <i>Histopathology</i> , 2015, 67, 20-38.	1.6	19
292	New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials. <i>Cancer Treatment Reviews</i> , 2015, 41, 614-622.	3.4	19
293	Inherited forms of bladder cancer: a review of Lynch syndrome and other inherited conditions. <i>Future Oncology</i> , 2018, 14, 277-290.	1.1	19
294	Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 685-693.	1.1	19
295	Emerging Prognostic Biomarkers in Testicular Germ Cell Tumors: Looking Beyond Established Practice. <i>Frontiers in Oncology</i> , 2018, 8, 571.	1.3	19
296	Digital frozen section of the prostate surface during radical prostatectomy: a novel approach to evaluate surgical margins. <i>BJU International</i> , 2020, 126, 336-338.	1.3	19
297	Metabolic Alterations in Renal and Prostate Cancer. <i>Current Drug Metabolism</i> , 2016, 17, 150-155.	0.7	19
298	“Insignificant” prostate cancer on prostatectomy and cystoprostatectomy: variation on a theme “low volume/ low grade” prostate cancer?. <i>BJU International</i> , 2010, 106, 304-315.	1.3	18
299	Urethral caruncle: a lesion related to IgG4-associated sclerosing disease?. <i>Journal of Clinical Pathology</i> , 2013, 66, 559-562.	1.0	18
300	Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. <i>European Urology</i> , 2016, 69, 186-190.	0.9	18
301	Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years. <i>Journal of Cancer</i> , 2017, 8, 323-331.	1.2	18
302	Should We Perform Multiparametric Magnetic Resonance Imaging of the Bladder Before Transurethral Resection of Bladder? Time to Reconsider the Rules. <i>European Urology</i> , 2019, 76, 57-58.	0.9	18
303	The Expression Patterns of p53 and p16 and an Analysis of a Possible Role of HPV in Primary Adenocarcinoma of the Urinary Bladder. <i>PLoS ONE</i> , 2014, 9, e95724.	1.1	18
304	Bladder Cancer: Molecular Determinants of Personalized Therapy. <i>Current Drug Targets</i> , 2015, 16, 115-124.	1.0	18
305	Automated Reasoning System in Histopathologic Diagnosis and Prognosis of Prostate Cancer and Its Precursors. <i>European Urology</i> , 1996, 30, 222-233.	0.9	17
306	Small cell“like change in prostatic intraepithelial neoplasia, intraductal carcinoma, and invasive prostatic carcinoma: a study of 7 cases. <i>Human Pathology</i> , 2013, 44, 427-431.	1.1	17

#	ARTICLE	IF	CITATIONS
307	SMARCB1/INI1 Genetic Alterations in Renal Medullary Carcinomas. <i>European Urology</i> , 2016, 69, 1062-1064.	0.9	17
308	Concomitant bladder cancer and prostate cancer: challenges and controversies. <i>Nature Reviews Urology</i> , 2017, 14, 620-629.	1.9	17
309	Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma. <i>Anticancer Research</i> , 2018, 38, 5773-5782.	0.5	17
310	Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. <i>Immunotherapy</i> , 2019, 11, 1507-1521.	1.0	17
311	Recurrent KRAS mutations are early events in the development of papillary renal neoplasm with reverse polarity. <i>Modern Pathology</i> , 2022, 35, 1279-1286.	2.9	17
312	Bicalutamide 50 mg monotherapy in patients with isolated high-grade PIN: findings in repeat biopsies at 6 months. <i>Journal of Clinical Pathology</i> , 2006, 60, 443-446.	1.0	16
313	Stage pT0 in Radical Prostatectomy with No Residual Carcinoma and with a Previous Positive Biopsy Conveys a Wrong Message to Clinicians and Patients: Why Is Cancer Not Present in the Radical Prostatectomy Specimen?. <i>European Urology</i> , 2009, 56, 272-274.	0.9	16
314	Influence of Histologic Criteria and Confounding Factors in Staging Equivocal Cases for Microscopic Perivesical Tissue Invasion (pT3a). <i>American Journal of Surgical Pathology</i> , 2014, 38, 167-175.	2.1	16
315	Small renal masses in the era of personalized medicine: Tumor heterogeneity, growth kinetics, and risk of metastasis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 303-309.	0.8	16
316	Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients. <i>World Journal of Urology</i> , 2017, 35, 517-526.	1.2	16
317	Variants of Bladder Cancer: The Pathologist's Point of View. <i>European Urology Supplements</i> , 2017, 16, 210-222.	0.1	16
318	Tivozanib for the treatment of renal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1021-1025.	0.9	16
319	PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives. <i>Current Drug Targets</i> , 2021, 22, 162-170.	1.0	16
320	Molecular Classification of Bladder Urothelial Carcinoma Using NanoString-Based Gene Expression Analysis. <i>Cancers</i> , 2021, 13, 5500.	1.7	16
321	Improving Inter-Observer Agreement and Certainty Level in Diagnosing and Grading Papillary Urothelial Neoplasms: Usefulness of a Bayesian Belief Network. <i>European Urology</i> , 2002, 41, 449-457.	0.9	15
322	2005 Update on Pathology of Prostate Biopsies with Cancer. <i>European Urology</i> , 2006, 49, 441-447.	0.9	15
323	Expression of prostate stem cell antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer. <i>Histopathology</i> , 2010, 57, 572-579.	1.6	15
324	Evidence for clonal fibroblast proliferation and autoimmune process in idiopathic retroperitoneal fibrosis. <i>Human Pathology</i> , 2012, 43, 1875-1880.	1.1	15

#	ARTICLE	IF	CITATIONS
325	Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 113.e1-113.e7.	0.8	15
326	Quality of Life After Prostate Cancer Diagnosis: Data from the Pros-IT CNR. <i>European Urology Focus</i> , 2017, 3, 321-324.	1.6	15
327	iatrogenic pathology of the urinary bladder. <i>Seminars in Diagnostic Pathology</i> , 2018, 35, 218-227.	1.0	15
328	Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers. <i>Cancers</i> , 2019, 11, 1225.	1.7	15
329	Relative Contribution of Sampling and Grading to the Quality of Prostate Biopsy: Results from a Single High-volume Institution. <i>European Urology Oncology</i> , 2020, 3, 474-480.	2.6	15
330	The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6237.	1.8	15
331	Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188547.	3.3	15
332	The Role of Artificial Intelligence in the Diagnosis and Prognosis of Renal Cell Tumors. <i>Diagnostics</i> , 2021, 11, 206.	1.3	15
333	T1 bladder carcinoma with variant histology: pathological features and clinical significance. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 989-998.	1.4	15
334	PATHOLOGICAL DEFINITION AND DIFFICULTIES IN ASSESSING POSITIVE MARGINS IN RADICAL PROSTATECTOMY SPECIMENS. <i>BJU International</i> , 2009, 103, 286-288.	1.3	14
335	Immunohistochemical expression of prostate tumor overexpressed 1 in cystoprostatectomies with incidental and insignificant prostate cancer.. <i>Human Pathology</i> , 2011, 42, 1931-1936.	1.1	14
336	Handling of radical prostatectomy specimens: total embedding with whole mounts, with special reference to the Ancona experience. <i>Histopathology</i> , 2011, 59, 1006-1010.	1.6	14
337	Handling of Radical Prostatectomy Specimens: Total Embedding with Large-Format Histology. <i>International Journal of Breast Cancer</i> , 2012, 2012, 1-6.	0.6	14
338	Immunohistochemical expression of prostate tumour overexpressed 1 (PTOV1) in atypical adenomatous hyperplasia (AAH) of the prostate. <i>Cellular Oncology (Dordrecht)</i> , 2013, 36, 37-42.	2.1	14
339	Re: Multilocular Cystic Renal Cell Carcinoma with Focus on Clinical and Pathobiological Aspects. <i>European Urology</i> , 2013, 63, 400-401.	0.9	14
340	The route to personalized medicine in bladder cancer: where do we stand?. <i>Targeted Oncology</i> , 2015, 10, 325-336.	1.7	14
341	Circulating tumor cells in genitourinary tumors. <i>Therapeutic Advances in Urology</i> , 2018, 10, 65-77.	0.9	14
342	Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment. <i>Seminars in Cancer Biology</i> , 2018, 52, 216-227.	4.3	14

#	ARTICLE	IF	CITATIONS
343	Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go. <i>Future Oncology</i> , 2019, 15, 2199-2202.	1.1	14
344	Liquid biopsy in the clinical management of bladder cancer: current status and future developments. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 255-264.	1.5	14
345	Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 141-150.	1.5	14
346	Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 755-763.	1.1	14
347	Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 491-501.	1.1	14
348	Epigenetic Modifications and Modulators in Prostate Cancer. <i>Critical Reviews in Oncogenesis</i> , 2017, 22, 439-450.	0.2	14
349	Italian Prostate Biopsies Group: 2016 Updated Guidelines Insights. <i>Anticancer Research</i> , 2017, 37, 413-424.	0.5	14
350	Evaluation of Prognostic Factors in Radical Prostatectomy Specimens with Cancer. <i>Urologia Internationalis</i> , 2002, 68, 209-215.	0.6	13
351	Clinicopathologic Characteristics of 23 Cases of Invasive Low-grade Papillary Urothelial Carcinoma. <i>Urology</i> , 2012, 80, 361-366.	0.5	13
352	Extent of Cancer of Less Than 50% in Any Prostate Needle Biopsy Core: How Many Millimeters Are There?. <i>European Urology</i> , 2012, 61, 751-756.	0.9	13
353	Renal cell carcinoma with rhabdoid features and loss of INI1 expression in an individual without sickle cell trait. <i>Pathology</i> , 2014, 46, 653-655.	0.3	13
354	Unlike in clear cell renal cell carcinoma, KRAS is not mutated in multilocular cystic clear cell renal cell neoplasm of low potential. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 687-693.	1.4	13
355	Whole Slide Imaging of Large Format Histology in Prostate Pathology: Potential for Information Fusion. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1460-1461.	1.2	13
356	MYB-NFIB gene fusion in prostatic basal cell carcinoma: clinicopathologic correlates and comparison with basal cell adenoma and florid basal cell hyperplasia. <i>Modern Pathology</i> , 2019, 32, 1666-1674.	2.9	13
357	Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer. <i>Cells</i> , 2020, 9, 2494.	1.8	13
358	Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives. <i>European Urology Focus</i> , 2021, 7, 955-963.	1.6	13
359	Bioptic intraprostatic chronic inflammation predicts adverse pathology at radical prostatectomy in patients with low-grade prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 793.e19-793.e25.	0.8	13
360	Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients. <i>Clinical Drug Investigation</i> , 2020, 40, 211-226.	1.1	13

#	ARTICLE	IF	CITATIONS
361	An update on investigational therapies that target STAT3 for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 245-251.	1.9	13
362	Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?. <i>Diagnostics</i> , 2021, 11, 138.	1.3	13
363	An Overview of Emerging Immunotargets of Genitourinary Tumors. <i>Current Drug Targets</i> , 2016, 17, 750-756.	1.0	13
364	Chromatin Phenotype Karyometry Can Predict Recurrence in Papillary Urothelial Neoplasms of Low Malignant Potential. <i>Analytical Cellular Pathology</i> , 2007, 29, 47-58.	0.7	13
365	An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13519.	1.8	13
366	Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations. <i>Future Oncology</i> , 2013, 9, 245-253.	1.1	12
367	EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder. <i>Modern Pathology</i> , 2014, 27, 107-112.	2.9	12
368	Genetic mutations in accordance with a low malignant potential tumour are not demonstrated in clear cell papillary renal cell carcinoma. <i>Journal of Clinical Pathology</i> , 2016, 69, 547-550.	1.0	12
369	Interpathologist concordance in the histological diagnosis of focal prostatic atrophy lesions, acute and chronic prostatitis, PIN, and prostate cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 711-715.	1.4	12
370	TFE3 Gene Rearrangement in Perivascular Epithelioid Cell Neoplasm (PEComa) of the Genitourinary Tract. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e692-e697.	0.9	12
371	Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5522.	1.8	12
372	PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay. <i>Current Drug Targets</i> , 2020, 21, 1664-1671.	1.0	12
373	Trpm8 Expression in Human and Mouse Castration Resistant Prostate Adenocarcinoma Paves the Way for the Preclinical Development of TRPM8-Based Targeted Therapies. <i>Biomolecules</i> , 2022, 12, 193.	1.8	12
374	Current and proposed biologic markers in prostate cancer. <i>Journal of Cellular Biochemistry</i> , 1992, 50, 65-67.	1.2	11
375	Molecular Techniques and Prostate Cancer Diagnostic. <i>European Urology</i> , 2003, 44, 390-400.	0.9	11
376	Immunohistochemical expression of somatostatin receptor subtypes in prostate tissue from cystoprostatectomies with incidental prostate cancer. <i>BJU International</i> , 2010, 106, 1072-1080.	1.3	11
377	Immunohistochemical analysis of chromatin remodeler DAXX in high grade urothelial carcinoma. <i>Diagnostic Pathology</i> , 2013, 8, 111.	0.9	11
378	Testing PD-1/PD-L1 Expression in Cancer Therapy: Pathologic Insights and Economic Sustainability. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 501-502.	1.2	11

#	ARTICLE	IF	CITATIONS
379	Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy. <i>Future Oncology</i> , 2020, 16, 75-80.	1.1	11
380	Added Clinical Value of Whole-mount Histopathology of Radical Prostatectomy Specimens: A Collaborative Review. <i>European Urology Oncology</i> , 2021, 4, 558-569.	2.6	11
381	Narrative review: update on immunotherapy and pathological features in patients with bladder cancer. <i>Translational Andrology and Urology</i> , 2021, 10, 1521-1529.	0.6	11
382	Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 33381-33390.	0.8	11
383	Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy. <i>Current Drug Metabolism</i> , 2019, 20, 305-312.	0.7	11
384	Morphologic and Molecular Backgrounds for Personalized Management of Genito-Urinary Cancers: An Overview. <i>Current Drug Targets</i> , 2015, 16, 96-102.	1.0	11
385	Correlation between High PD-L1 and EMT/Invasive Genes Expression and Reduced Recurrence-Free Survival in Blood-Circulating Tumor Cells from Patients with Non-Muscle-Invasive Bladder Cancer. <i>Cancers</i> , 2021, 13, 5989.	1.7	11
386	Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis. <i>Future Oncology</i> , 2022, 18, 739-748.	1.1	11
387	Karyometry detects subvisual differences in chromatin organization state between cribriform and flat high-grade prostatic intraepithelial neoplasia. <i>Modern Pathology</i> , 2004, 17, 928-937.	2.9	10
388	Decision support systems for morphology-based diagnosis and prognosis of prostate neoplasms. <i>Cancer</i> , 2009, 115, 3068-3077.	2.0	10
389	Genetic profiles in renal tumors. <i>International Journal of Urology</i> , 2010, 17, 6-19.	0.5	10
390	Does prostate acinar adenocarcinoma with Gleason Score 3 + 3 = 6 have the potential to metastasize?. <i>Diagnostic Pathology</i> , 2014, 9, 190.	0.9	10
391	Total submission of lymphadenectomy tissues removed during radical prostatectomy for prostate cancer: possible clinical significance of large-format histology. <i>Human Pathology</i> , 2014, 45, 2059-2062.	1.1	10
392	Re: Epithelial-to-mesenchymal Transition in Renal Neoplasms. <i>European Urology</i> , 2015, 68, 736-737.	0.9	10
393	Present and future of personalized medicine in adult genitourinary tumors. <i>Future Oncology</i> , 2015, 11, 1381-1388.	1.1	10
394	A contemporary series of renal masses with emphasis on recently recognized entities and tumors of low malignant potential: A report based on 624 consecutive tumors from a single tertiary center. <i>Pathology Research and Practice</i> , 2017, 213, 804-808.	1.0	10
395	Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic Approach. <i>European Urology Supplements</i> , 2017, 16, 309-315.	0.1	10
396	Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 131, 1-6.	2.0	10

#	ARTICLE	IF	CITATIONS
397	Prostate cancer grading in 2018: limitations, implementations, cribriform morphology, and biological markers. <i>International Journal of Biological Markers</i> , 2018, 33, 331-334.	0.7	10
398	Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). <i>Tumori</i> , 2019, 105, 3-12.	0.6	10
399	Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the Grade Groups?. <i>Translational Andrology and Urology</i> , 2021, 10, 1530-1540.	0.6	10
400	Emerging Immunotargets and Immunotherapies in Prostate Cancer. <i>Current Drug Targets</i> , 2016, 17, 777-782.	1.0	10
401	Immunotherapy and Radiation Therapy in Renal Cell Carcinoma. <i>Current Drug Targets</i> , 2020, 21, 1463-1475.	1.0	10
402	Overview of potential determinants of radical prostatectomy versus radiation therapy in management of clinically localized prostate cancer: results from an Italian, prospective, observational study (the Tj ETQqO 0 0 rgBT/Overlock 10 Tf 50). <i>Translational Andrology and Urology</i> , 2020, 72, 595-604.	0.9	10
403	Renal oncocytosis and multiple papillary adenomas with oncocytoma as dominant nodule coexisting with papillary carcinoma in a patient with diabetic glomerulosclerosis, acquired renal cystic disease and B cell lymphoma. <i>Apmis</i> , 2008, 116, 934-938.	0.9	9
404	Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications. <i>Seminars in Diagnostic Pathology</i> , 2008, 25, 232-244.	1.0	9
405	Phase I-II Trial of Weekly Bicalutamide in Men with Elevated Prostate-Specific Antigen and Negative Prostate Biopsies. <i>Cancer Prevention Research</i> , 2009, 2, 377-384.	0.7	9
406	How much do you know about benign, preneoplastic, non-invasive and invasive neoplastic lesions of the urinary bladder classified according to the 2004 WHO scheme?. <i>Diagnostic Pathology</i> , 2011, 6, 31.	0.9	9
407	The Importance of Interaction Between Urologists and Pathologists in Incidental Prostate Cancer Management. <i>European Urology</i> , 2011, 60, 75-77.	0.9	9
408	Pathology and molecular updates in tumors of the prostate: towards a personalized approach. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 781-789.	1.5	9
409	Digital versus light microscopy assessment of surgical margin status after radical prostatectomy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 451-460.	1.4	9
410	A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 569-577.	1.6	9
411	Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, S137-S137.	0.7	9
412	Ciliary neurotrophic factor (CNTF) and its receptor (CNTFR $\pm$ ) signal through MAPK/ERK pathway in human prostate tissues: a morphological and biomolecular study. <i>European Journal of Histochemistry</i> , 2020, 64, .	0.6	9
413	Immunotherapy for urothelial cancer: from the diagnostic pathologist's point of view. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 539-544.	1.4	9
414	Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications. <i>Frontiers in Genetics</i> , 2020, 11, 349.	1.1	9

#	ARTICLE	IF	CITATIONS
415	Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications. <i>Modern Pathology</i> , 2021, 34, 1384-1391.	2.9	9
416	Prostate Cancer in 2021: Novelty in Prognostic and Therapeutic Biomarker Evaluation. <i>Cancers</i> , 2021, 13, 3471.	1.7	9
417	Emerging Immunotargets in Bladder Cancer. <i>Current Drug Targets</i> , 2016, 17, 757-770.	1.0	9
418	Pathological Findings in TRUS Prostatic Biopsy – Diagnostic, Prognostic and Therapeutic Importance. <i>European Urology Supplements</i> , 2002, 1, 60-75.	0.1	8
419	Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer. <i>Cellular Oncology (Dordrecht)</i> , 2011, 34, 235-243.	2.1	8
420	Role of histopathology and molecular markers in the active surveillance of prostate cancer. <i>Acta Oncologica</i> , 2011, 50, 56-60.	0.8	8
421	Combined handling of prostate base/bladder neck and seminal vesicles in radical prostatectomy specimens: our approach with the whole mount technique. <i>Histopathology</i> , 2013, 63, 431-435.	1.6	8
422	A Better Understanding of the Morphological Features and Molecular Characteristics of Intraductal Carcinoma Helps Clinicians Further Explain Prostate Cancer Aggressiveness. <i>European Urology</i> , 2015, 67, 504-507.	0.9	8
423	Quantitative Image Analysis on Histologic Virtual Slides for Prostate Pathology Diagnosis, Response to Chemopreventive Agents, and Prognosis. <i>European Urology Focus</i> , 2017, 3, 467-469.	1.6	8
424	Renal cell carcinoma in one year: Going inside the news of 2017 – A report of the main advances in RCC cancer research. <i>Cancer Treatment Reviews</i> , 2018, 67, 29-33.	3.4	8
425	Upper urinary tract urothelial carcinoma and its variants: transition from morphology to personalized molecular characterization in diagnosis, prognosis, and therapy. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 1021-1028.	1.5	8
426	Treatment paths for localised prostate cancer in Italy: The results of a multidisciplinary, observational, prospective study (Pros-IT CNR). <i>PLoS ONE</i> , 2019, 14, e0224151.	1.1	8
427	Histopathologic challenges: The second OPINION issue. <i>European Journal of Surgical Oncology</i> , 2019, 45, 12-15.	0.5	8
428	Exploring the Spectrum of Kidney Ciliopathies. <i>Diagnostics</i> , 2020, 10, 1099.	1.3	8
429	Urologists During the COVID-19 Pandemic: What Can Be Learned in Terms of Social Interaction, Visibility, and Social Distance. <i>European Urology</i> , 2020, 78, 478-481.	0.9	8
430	Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. <i>Cells</i> , 2020, 9, 1495.	1.8	8
431	pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 3-16.	1.4	8
432	Predicting future cancer burden in the United States by artificial neural networks. <i>Future Oncology</i> , 2021, 17, 159-168.	1.1	8

#	ARTICLE	IF	CITATIONS
433	Current and future perspectives of digital microscopy with fluorescence confocal microscope for prostate tissue interpretation: a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 1569-1580.	0.6	8
434	Updated pathology reporting standards for bladder cancer: biopsies, transurethral resections and radical cystectomies. <i>World Journal of Urology</i> , 2022, 40, 915-927.	1.2	8
435	Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 273.e11-273.e20.	0.8	8
436	PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What's Now, What's New, and What's Coming?. <i>Cancers</i> , 2022, 14, 907.	1.7	8
437	Human papillomavirus (HPV)-induced neoplasia in the urinary bladder: a missing link?. <i>Histology and Histopathology</i> , 2016, 31, 595-600.	0.5	8
438	Small cell carcinoma of the prostate: molecular basis and clinical implications. <i>Histology and Histopathology</i> , 2015, 30, 413-24.	0.5	8
439	Lymphocytic vasculitis of the prostate transition zone. <i>BJU International</i> , 2012, 110, 1775-1780.	1.3	7
440	Perivascular epithelioid cell tumor (PEC-ome) of the prostate: Ultrasound feature in case report. <i>Archivio Italiano Di Urologia Andrologia</i> , 2014, 86, 393.	0.4	7
441	A low grade PIN-like neoplasm of the transition zone immunohistochemically negative for basal cell markers: a possible example of low grade adenocarcinoma with stratified epithelium. <i>Pathology</i> , 2014, 46, 88-91.	0.3	7
442	Pseudocarcinomatous hyperplasia associated with primary lymphoma in the urinary bladder: a case report. <i>Human Pathology</i> , 2015, 46, 1040-1044.	1.1	7
443	Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: "Game Over"? <i>Targeted Oncology</i> , 2016, 11, 431-446.	1.7	7
444	Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?. <i>Future Oncology</i> , 2018, 14, 2997-2999.	1.1	7
445	Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721881537.	0.9	7
446	Combination of Multiparametric Magnetic Resonance Imaging With Elastic-fusion Biopsy Has a High Sensitivity in Detecting Clinically Significant Prostate Cancer in Daily Practice. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e501-e509.	0.9	7
447	Grading of Chromophobe Renal Cell Carcinoma: Do We Need It?. <i>European Urology</i> , 2021, 79, 232-233.	0.9	7
448	Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma. <i>Asian Journal of Andrology</i> , 2011, 13, 242-247.	0.8	7
449	Liquid Biopsies in the Management of Bladder Cancer: Next-Generation Biomarkers for Diagnosis, Surveillance, and Treatment-Response Prediction. <i>Critical Reviews in Oncogenesis</i> , 2017, 22, 389-401.	0.2	7
450	Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?. <i>Current Drug Metabolism</i> , 2017, 18, 692-699.	0.7	7

#	ARTICLE	IF	CITATIONS
451	Metabolomic Profiling in Renal Cell Carcinoma Patients: News and Views. <i>Cancers</i> , 2021, 13, 5229.	1.7	7
452	Immunohistochemical detection and localization of somatostatin receptor subtypes in prostate tissue from patients with bladder outlet obstruction. <i>Cellular Oncology</i> , 2008, 30, 473-82.	1.9	7
453	Inference network-based analyses of the histopathological effects of androgen deprivation on prostate cancer. , 1999, 187, 462-468.		6
454	Recurrent papillary urothelial neoplasm of low malignant potential. Subtle architectural disorder detected by quantitative analysis in DAXX-immunostained tissue sections. <i>Human Pathology</i> , 2014, 45, 745-752.	1.1	6
455	Multiple and bilateral kidney tumors with clear cells of three different histotypes: A case report with clinicopathologic and molecular study. <i>Apmis</i> , 2016, 124, 619-623.	0.9	6
456	Immunotargeting and personalized therapies in genitourinary cancers. <i>Future Oncology</i> , 2016, 12, 1853-1856.	1.1	6
457	Re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. <i>Eur Urol</i> 2015;68:912-4. <i>European Urology</i> , 2016, 70, e72-e74.	0.9	6
458	Activity and Functions of Tumor-associated Macrophages in Prostate Carcinogenesis. <i>European Urology Supplements</i> , 2017, 16, 301-308.	0.1	6
459	<i>TMPRSS2-ERG</i> gene fusion is rare compared to <i>PTEN</i> deletions in stage T1a prostate cancer. <i>Molecular Carcinogenesis</i> , 2017, 56, 814-820.	1.3	6
460	Re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. <i>Eur Urol</i> 2016;70:738-9. <i>European Urology</i> , 2017, 71, e73-e75.	0.9	6
461	Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014). <i>BMC Cancer</i> , 2017, 17, 493.	1.1	6
462	Intratumoural heterogeneity may hinder precision medicine strategies in patients with clear cell renal cell carcinoma. <i>Journal of Clinical Pathology</i> , 2018, 71, 467-471.	1.0	6
463	Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. <i>Future Oncology</i> , 2018, 14, 2559-2564.	1.1	6
464	Re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. <i>Eur Urol</i> 2019;75:667-75. <i>European Urology</i> , 2019, 76, e69-e72.	0.9	6
465	Prostate cancer pathology: What has changed in the last 5 years. <i>Urologia</i> , 2020, 87, 3-10.	0.3	6
466	Designing novel immunocombinations in metastatic renal cell carcinoma. <i>Immunotherapy</i> , 2020, 12, 1257-1268.	1.0	6
467	Pathology without microscope: From a projection screen to a virtual slide. <i>Pathology Research and Practice</i> , 2020, 216, 153196.	1.0	6
468	New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?. <i>Cells</i> , 2020, 9, 1522.	1.8	6

#	ARTICLE	IF	CITATIONS
469	Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 295.e1-295.e8.	0.8	6
470	Digital diagnostics and artificial intelligence in prostate cancer treatment in 5 years from now. <i>Translational Andrology and Urology</i> , 2021, 10, 1499-1505.	0.6	6
471	TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like?â€”a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 1541-1552.	0.6	6
472	Incidental Prostate Cancer (cT1aâ€”cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines. <i>European Urology Oncology</i> , 2021, , .	2.6	6
473	Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma. <i>Current Drug Targets</i> , 2020, 21, 416-423.	1.0	6
474	PD1/PD-L1 Axis in Uro-oncology. <i>Current Drug Targets</i> , 2020, 21, 1293-1300.	1.0	6
475	Molecular Characterization of Testicular Germ Cell Tumors Using Tissue Microdissection. <i>Methods in Molecular Biology</i> , 2021, 2195, 31-47.	0.4	6
476	Bladder Cancer Sample Handling and Reporting: Pathologist's Point of View. <i>Frontiers in Surgery</i> , 2021, 8, 754741.	0.6	6
477	ETS-related gene (ERG) undermines genome stability in mouse prostate progenitors via Gsk3 <sup>Î²</sup> dependent Nrx3.1 degradation. <i>Cancer Letters</i> , 2022, 534, 215612.	3.2	6
478	Radical prostatectomy specimen processing: A critical appraisal of sampling methods. <i>Current Diagnostic Pathology</i> , 2007, 13, 490-498.	0.4	5
479	Splitting and Lumping Adult Renal Epithelial Tumours: Is That What the Urologists Want?. <i>European Urology</i> , 2008, 53, 673-675.	0.9	5
480	Re: Peripheral Zone Prostate Cancers: Location and Intraprostatic Patterns of Spread at Histopathology. <i>European Urology</i> , 2010, 58, 180-182.	0.9	5
481	Urological pathology comes of age. <i>Pathology</i> , 2012, 44, 389-390.	0.3	5
482	Re: Antibody-drug Conjugates Targeting Prostate-specific Membrane Antigen. <i>European Urology</i> , 2014, 66, 1190-1193.	0.9	5
483	Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus. <i>Future Oncology</i> , 2015, 11, 2711-2719.	1.1	5
484	Prostate cancer glands with cribriform architecture and with glomeruloid features should be considered as Gleason pattern 4 and not pattern 3. <i>Future Oncology</i> , 2016, 12, 1431-1433.	1.1	5
485	MÃ¼llerian Adenosarcoma of the Urinary Bladder: Clinicopathologic and Immunohistochemical Features With Novel Genetic Aberrations. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1007-e1014.	0.9	5
486	From Gleason Grading System and High-grade Tertiary Patterns to Grade Groups and Integrated Quantitative Gleason Score. <i>European Urology</i> , 2018, 73, 684-686.	0.9	5

#	ARTICLE	IF	CITATIONS
487	Molecular evidence supporting the precursor nature of atypical adenomatous hyperplasia of the prostate. <i>Molecular Carcinogenesis</i> , 2019, 58, 1272-1278.	1.3	5
488	Liquid biopsies in urological cancers: what we need to know before starting using them. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 135-139.	1.5	5
489	An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 207-217.	1.5	5
490	Chromophobe Renal Cell Carcinoma Aggressiveness and Immuno-oncology Therapy: How to Distinguish the Good One from the Bad One. <i>European Urology Oncology</i> , 2021, 4, 331-333.	2.6	5
491	Re: J. Alfred Witjes, Harman Max Bruins, Richard Cathomas, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. <i>Eur Urol</i> 2021;79:82â€“104. <i>European Urology</i> , 2021, 79, e30-e32.	0.9	5
492	Impact of Gastrointestinal Side Effects on Patientsâ€™ Reported Quality of Life Trajectories after Radiotherapy for Prostate Cancer: Data from the Prospective, Observational Pros-IT CNR Study. <i>Cancers</i> , 2021, 13, 1479.	1.7	5
493	Lesson from the COVID-19 pandemic: pathologists need to build their confidence on working in a digital microscopy environment. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 227-229.	1.4	5
494	Fluorescence In Situ Hybridization (FISH) Detection of Chromosomal 12p Anomalies in Testicular Germ Cell Tumors. <i>Methods in Molecular Biology</i> , 2021, 2195, 49-63.	0.4	5
495	HER-2 expression and gene amplification in high-grade PIN and prostate cancer. <i>Archivio Italiano Di Urologia Andrologia</i> , 2006, 78, 135-9.	0.4	5
496	Active surveillance for low-risk prostate cancer. <i>Anticancer Research</i> , 2010, 30, 3683-92.	0.5	5
497	Health-related quality of life 24 months after prostate cancer diagnosis: an update from the Pros-IT CNR prospective observational study. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	1.3	5
498	Updates in Grading of Renal Cell Carcinomas Beyond Clear Cell Renal Cell Carcinoma and Papillary Renal Cell Carcinoma. <i>Advances in Anatomic Pathology</i> , 2022, 29, 117-130.	2.4	5
499	Current androgen receptor antagonists under investigation for resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 191-202.	1.1	5
500	Macrocryosectioning and complete sampling of the prostate in a potential multiorgan donor candidate. <i>Journal of Clinical Pathology</i> , 2006, 60, 951-952.	1.0	4
501	Editorial Comment on: Prognostic Significance of Gleason Score Discrepancies between Needle Biopsy and Radical Prostatectomy. <i>European Urology</i> , 2008, 53, 775-776.	0.9	4
502	â€œPathologicalâ€•Reflection on European Urology: Extended, Saturation, and Systematic Prostate Biopsies. <i>European Urology</i> , 2008, 53, 1111-1114.	0.9	4
503	Changes in chromatin phenotype predict the response to hormonal deprivation therapy in patients with prostate cancer. <i>BJU International</i> , 2009, 103, 391-398.	1.3	4
504	A randomized phase IIb presurgical study of finasteride vs. low-dose flutamide vs. placebo in men with prostate cancer. Efficacy monitored by karyometry. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 557-565.	0.8	4

#	ARTICLE	IF	CITATIONS
505	Somatostatin receptor expression in prostate carcinoma: the urological pathologist's role in the era of personalised medicine. <i>Pathology</i> , 2013, 45, 93-96.	0.3	4
506	Re: Johan Lindberg, Anna Kristiansen, Peter Wiklund, Henrik Grønberg, Lars Egevad. Tracking the Origin of Metastatic Prostate Cancer. <i>Eur Urol</i> 2015;67:819-22. <i>European Urology</i> , 2015, 68, e134-e135.	0.9	4
507	Editorial (Thematic Issue: Emerging Immunotargets in Genitourinary Tumors). <i>Current Drug Targets</i> , 2016, 17, 748-749.	1.0	4
508	Clinical impact of tumoral angiogenesis on renal cell carcinoma management: where do we stand?. Expert Review of Precision Medicine and Drug Development, 2016, 1, 229-231.	0.4	4
509	Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets. <i>Future Oncology</i> , 2017, 13, 1105-1114.	1.1	4
510	Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View. <i>European Urology Supplements</i> , 2017, 16, 223-231.	0.1	4
511	Prognostic role of BAP1 in pT1 clear cell carcinoma in partial nephrectomy specimens. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 99-105.	1.4	4
512	Editorial: Emerging Biomarkers in Genitourinary Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 326.	1.3	4
513	Re: Multi-institutional Re-evaluation of Prognostic Factors in Chromophobe Renal Cell Carcinoma: Proposal of a Novel Two-tiered Grading Scheme. <i>European Urology</i> , 2020, 78, 114-116.	0.9	4
514	Molecular diagnostics in uro-oncology. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 117-121.	1.5	4
515	Exciting experiences in the Rocky road to digital diagnostics™. <i>Journal of Clinical Pathology</i> , 2021, 74, 5-6.	1.0	4
516	Agent-Based Learning Model for the Obesity Paradox in RCC. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 642760.	2.0	4
517	Surgical pathology of cystic renal cell carcinomas: is there an overestimation of malignancy?. <i>Diagnostic Histopathology</i> , 2020, 26, 320-329.	0.2	4
518	Recent Advances in the Quantitative Morphological Evaluation of Prostate Neoplasia. <i>Journal of Urologic Pathology</i> , 2000, 12, 133-168.	0.3	4
519	PD-L1 Inhibitors for the Treatment of Prostate Cancer. <i>Current Drug Targets</i> , 2020, 21, 1558-1565.	1.0	4
520	Update on Prostate Cancer Diagnosis, Prognosis, and Prediction to Response to Therapy. <i>Cells</i> , 2021, 10, 20.	1.8	4
521	Seminal Vesicle Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1296, 309-318.	0.8	4
522	AT-rich interactive domain 1A (ARID1A) cannot be considered a morphological marker for prostate cancer progression: A pilot study. <i>Acta Histochemica</i> , 2022, 124, 151847.	0.9	4

#	ARTICLE	IF	CITATIONS
523	Target populations, pathological biomarkers and chemopreventive agents in prostate cancer prevention. <i>Archivio Italiano Di Urologia Andrologia</i> , 2003, 75, 127-34.	0.4	4
524	Histomorphometry and Pattern Recognition Analysis of Urothelial Papillary Lesions. <i>Tumori</i> , 1984, 70, 463-466.	0.6	3
525	Editorial Comment on: Expression of the Endothelin Axis in Noninvasive and Superficially Invasive Bladder Cancer: Relation to Clinicopathologic and Molecular Prognostic Parameters. <i>European Urology</i> , 2009, 56, 846-847.	0.9	3
526	The Gleason grading system: where are we now?. <i>Diagnostic Histopathology</i> , 2011, 17, 419-427.	0.2	3
527	Rare Tumors and Tumor-like Conditions in Urological Pathology. , 2015, , .		3
528	Clinical implications of a rare renal entity: Pleomorphic Hyalinizing Angiectatic Tumor (PHAT). <i>Pathology Research and Practice</i> , 2017, 213, 165-169.	1.0	3
529	Considerations for standardizing predictive molecular pathology for cancer prognosis. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 47-55.	1.5	3
530	Variants and Variations in Epithelial Renal Cell Tumors in Adults: The Pathologist's Point of View. <i>European Urology Supplements</i> , 2017, 16, 232-240.	0.1	3
531	Serous Carcinoma Mimicking Primary Urothelial Carcinoma on Clinical Evaluation and Pathology: A Potential Diagnostic Pitfall. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 168-177.	1.2	3
532	Re: Isabel Rauscher, Charlotte DÄ¼wel, Bernhard Haller, et al. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigenâ€“ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. <i>Eur Urol</i> 2018;73:656â€“61. <i>European Urology</i> , 2018, 74, e141-e144.	0.9	3
533	Prostate Cancer Grading: Are We Heading Towards Grade Grouping Version 2?. <i>European Urology</i> , 2019, 75, 32-34.	0.9	3
534	Predicting biochemical recurrence after radical prostatectomy: the role of prognostic grade group and index tumor nodule. <i>Human Pathology</i> , 2019, 93, 6-15.	1.1	3
535	Digital versus light microscopy assessment of extraprostatic extension in radical prostatectomy samples. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 735-744.	1.4	3
536	Inguinal bladder hernia with lipomatosis of the bladder wall: A potential clinical pitfall for cancer. <i>Urologia</i> , 2019, 86, 35-38.	0.3	3
537	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 917-927.	0.6	3
538	Re: Friederike Haidl, David Pfister, Axel Heidenreich. Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. Mordasini L, Hechelhammer L, Diener PA, et al. <i>J Vasc Interv Radiol</i> 2018;29:589â€“97. <i>Eur Urol</i> 2018;74:525â€“6. <i>European Urology</i> , 2019, 75, e110-e113.	0.9	3
539	Neoplasms of the Urinary Bladder. , 2020, , 230-321.e19.		3
540	Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?. <i>Translational Andrology and Urology</i> , 2021, 10, 1581-1587.	0.6	3

#	ARTICLE	IF	CITATIONS
541	Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis. <i>Immunotherapy</i> , 2021, 13, 783-793.	1.0	3
542	Seminal vesicle cystadenoma with dysplasia: missing link to adenocarcinoma?. <i>Histopathology</i> , 2021, 79, 274-276.	1.6	3
543	Re: Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy. <i>European Urology</i> , 2021, 79, 887-889.	0.9	3
544	Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough. <i>Cancers</i> , 2021, 13, 3492.	1.7	3
545	Urinary Biomarkers for Prostate Cancer. <i>Current Drug Metabolism</i> , 2017, 18, 723-726.	0.7	3
546	Health-related quality of life 24-month after prostate cancer diagnosis: an update from the Pros-IT CNR prospective observational study. <i>Minerva Urology and Nephrology</i> , 2021, , .	1.3	3
547	Extramammary Paget disease of the penis closely mimicking the penile analogue of stratified mucin-producing intraepithelial lesion. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019, 71, 189-190.	3.9	3
548	Knowledge discovery processing and data mining in karyometry. , 2009, 31, 125-36.		3
549	Prognostic Value of Computerized DNA Analysis in Noninvasive Papillary Carcinomas of the Urinary Bladder. <i>Tumori</i> , 1987, 73, 567-574.	0.6	2
550	Editorial Comment on: Prediction of Progression of Non-Muscle-Invasive Bladder Cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective Study. <i>European Urology</i> , 2008, 54, 843-844.	0.9	2
551	Pathological issues in biopsy specimens of men with prostate cancer eligible for active surveillance. <i>Archivio Italiano Di Urologia Andrologia</i> , 2014, 86, 314.	0.4	2
552	Genitourinary Cancers: Molecular Determinants for Personalized Therapies. <i>Urologia</i> , 2016, 83, 107-109.	0.3	2
553	Grading of Prostate Cancer in the 21 <sup>st</sup> Century. <i>Urologia</i> , 2016, 83, 1-3.	0.3	2
554	Synchronous clear cell renal cell carcinoma and multilocular cystic renal cell neoplasia of low malignant potential: A clinico-pathologic and molecular study. <i>Pathology Research and Practice</i> , 2016, 212, 471-474.	1.0	2
555	The role of precision medicine for the treatment of metastatic renal cell carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 369-377. Re: Kenneth A. Iczkowski's Letter to the Editor re: Re: Rodolfo Montironi, Silvia Gasparrini, Roberta Mazzucchelli, et al's Letter to the Editor re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. <i>Eur Urol</i> 2016;70:738-739; Sentinel Lymph Nodes in Adipose Tissue Surrounding the Prostate Gland and Seminal Vesicles as Observed in Virtual Whole-mount Histologic Slides. <i>Eur Urol</i> 2017;71:e73-75. <i>European Urology</i> , 2017, 72, e37-e38.	0.4	2
556	Clinical Trials for Specific Renal Cancer Subtypes-The Time Will Come!. <i>European Urology Supplements</i> , 2017, 16, 241-252.	0.9	2
557	Clinical Trials for Specific Renal Cancer Subtypes-The Time Will Come!. <i>European Urology Supplements</i> , 2017, 16, 241-252.	0.1	2
558	Immunotherapy in genitourinary cancers: where are we going?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 73-78.	0.4	2

#	ARTICLE	IF	CITATIONS
559	Editorial: Emerging Biomarkers in Genitourinary Tumors. <i>Current Drug Metabolism</i> , 2017, 18, 690-691.	0.7	2
560	Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George's Letter to the Editor re: Arnaud MÃ©jean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. <i>Eur Urol</i> 2018;74:842â€“3. <i>European Urology</i> , 2019, 75, e64-e66.	0.9	2
561	Re: Maud Rijnders, Astrid A.M. van der Veldt, Tahlita C.M. Zuiverloon, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. <i>Eur Urol</i> 2019;75:538â€“40. <i>European Urology</i> , 2019, 75, e162-e163.	0.9	2
562	Potential biomarkers and risk assessment models to enhance the tumor-node-metastasis (TNM) staging classification of urologic cancers. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 921-932.	1.5	2
563	Preimplantation Factor immunohistochemical expression correlates with prostate cancer aggressiveness. <i>International Journal of Biological Markers</i> , 2020, 35, 82-90.	0.7	2
564	Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States. <i>Translational Andrology and Urology</i> , 2021, 10, 1562-1568.	0.6	2
565	An update on immunotherapy in uro-oncology. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 229-233.	0.4	2
566	The Pathology of Prostate Cancer. , 2010, , 45-83.		2
567	Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians. <i>Asian Journal of Andrology</i> , 2019, 21, 19.	0.8	2
568	Contemporary update on pathology-related issues on routine workup of prostate biopsy: sectioning, tumor extent measurement, specimen orientation, and immunohistochemistry. <i>Analytical and Quantitative Cytopathology and Histopathology</i> , 2014, 36, 61-70.	0.2	2
569	Re: AurÃ©lien Descazeaud, Marc Zerbib, Thierry Flam et al. Can pT0 Stage of Prostate Cancer be Predicted before Radical Prostatectomy? <i>Eur Urol</i> 2006;50:1248â€“53. <i>European Urology</i> , 2007, 52, 294-295.	0.9	1
570	Re: Radial Distance of Extraprostatic Extension Measured by Ocular Micrometer is an Independent Predictor of Prostate-Specific Antigen Recurrence. A New Proposal for the Substaging of pT3a Prostate Cancer. <i>European Urology</i> , 2008, 53, 449-450.	0.9	1
571	Bladder cancer: pathogenesis. <i>Scandinavian Journal of Urology and Nephrology</i> , 2008, 42, 93-94.	1.4	1
572	Editorial Comment on: Prevalence of a Tertiary Gleason Grade and Its Impact on Adverse Histopathologic Parameters in a Contemporary Radical Prostatectomy Series. <i>European Urology</i> , 2009, 55, 402.	0.9	1
573	Reply to JosÃ© I. LopÃ©z's Letter to the Editor re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Stage pT0 in Radical Prostatectomy with No Residual Carcinoma and with a Previous Positive Biopsy Conveys a Wrong Message to Clinicians and Patients: Why Is Cancer Not Present in the Radical Prostatectomy Specimen? <i>Eur Urol</i> 2009;56:272â€“4. <i>European Urology</i> , 2010, 57, e22-e23.	0.9	1
574	â€œNo Pay, No Playâ€ or From â€œDefensive or Passive Pathologyâ€ to â€œActive, Clinically Oriented Pathologyâ€ <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 1474-1475.	1.2	1
575	Re: â€œNo Pay, No Playâ€: The End of Professional Ethics in Pathology?. <i>European Urology</i> , 2012, 61, 424-425.	0.9	1
576	Editorial Comment from Dr Montironi <i>et al.</i> to Malignant mixed epithelial and stromal tumor of the kidney: Report of the first male case. <i>International Journal of Urology</i> , 2013, 20, 451-452.	0.5	1

#	ARTICLE	IF	CITATIONS
577	Editorial (Mini-Thematic Issue: Morphological and Molecular Backgrounds for Personalized Therapies) Tj ETQq1 1 0.784314 rgBT /Ove	1.0	1
578	The Prostate and Seminal Vesicles. , 2015, , 195-310.		1
579	Re: Umberto Leone Roberti Maggiore, Simone Ferrero, Massimo Candiani, et al. Bladder Endometriosis: A Systematic Review of Pathogenesis, Diagnosis, Treatment, Impact on Fertility, and Risk of Malignant Transformation. Eur Urol 2017;71:790â€“807. European Urology, 2017, 72, e139-e141.	0.9	1
580	Prospects for precision therapy of bladder urothelial carcinoma. Expert Review of Precision Medicine and Drug Development, 2017, 2, 261-274.	0.4	1
581	Re: Daniel M. Geynisman. Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features. Eur Urol 2015;68:912â€“4. European Urology, 2017, 71, e27-e28.	0.9	1
582	From Undergraduate Medical School Student to Visible Pathologist. Archives of Pathology and Laboratory Medicine, 2020, 144, 413-414.	1.2	1
583	Renal Cell Carcinoma: genomic landscape and clinical implications. Expert Review of Precision Medicine and Drug Development, 2020, 5, 95-100.	0.4	1
584	Re: Alfonso GÃ3mez de LiaÃ±o Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Antiâ€“PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269â€“76. European Urology, 2021, 79, e17-e19.	0.9	1
585	Considerations on current and future issues related to reproducibility and accuracy in prostate cancer grading. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 375-377.	1.4	1
586	Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. Eur Urol 2021;79:489â€“91. European Urology, 2021, 79, e172-e173.	0.9	1
587	The Coronavirus Disease 2019 (COVID-19) Pandemic's Impact on Social Interaction in Pathology. Archives of Pathology and Laboratory Medicine, 2021, 145, 1049-1050.	1.2	1
588	Digital whole mount sections of the prostate: heading towards new ways of communicating with clinicians and patients without microscope. Minerva Urology and Nephrology, 2021, , .	1.3	1
589	Re: Bas W.G. van Rhijn, Anouk E. Hentschel, Johannes BrÃ¼ndl, et al. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Nonâ€“muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Nonâ€“muscle-invasive Bladder Cancer Guidelines Panel Study. Eur Urol Oncol 2021;4:182â€“91. European Urology Oncology, 2021, 4, 671-673.	2.6	1
590	Reply to Eoin Dinneen, Jon Oxley, and Greg Shawâ€™s Letter to the Editor re: Bernardo Rocco, Luca Sarchi, Simone Assumma, et al. Digital Frozen Sections with Fluorescence Confocal Microscopy During Robot-assisted Radical Prostatectomy: Surgical Technique. Eur Urol. In press. <a href="https://doi.org/10.1016/j.eururo.2021.03.021">https://doi.org/10.1016/j.eururo.2021.03.021</a> . European Urology, 2021, 80, e122-e123.	0.9	1
591	Liquid biopsies in renal cell carcinoma with focus on epigenome analysis. Annals of Translational Medicine, 2019, 7, S194-S194.	0.7	1
592	The waiting time for prostate cancer treatment in Italy: analysis from the Pros-IT CNR study. Minerva Urology and Nephrology, 2020, , .	1.3	1
593	Bayesian belief network for the Gleason patterns in prostatic adenocarcinoma: development of a diagnostic decision support system for educational purposes. , 2008, 30, 8-15.		1
594	The waiting time for prostate cancer treatment in Italy: analysis from the PROS-IT CNR Study. Minerva Urology and Nephrology, 2022, 74, .	1.3	1

#	ARTICLE	IF	CITATIONS
595	Artificial intelligence and prostate cancer: Advances and challenges. <i>Urologia</i> , 2021, , 039156032110624.	0.3	1
596	Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis. <i>Tumori</i> , 2023, 109, 157-163.	0.6	1
597	Digital Knowledge and Diagnostic Information. <i>Microscopy and Microanalysis</i> , 2000, 6, 1008-1009.	0.2	0
598	Editorial Comment on: Validation of the Contemporary Epstein Criteria for Insignificant Prostate Cancer in European Men. <i>European Urology</i> , 2008, 54, 1311-1312.	0.9	0
599	Editorial Comment on: Comparing the Gleason Prostate Biopsy and Gleason Prostatectomy Grading System: The Lahey Clinic Medical Center Experience and an International Meta-analysis. <i>European Urology</i> , 2008, 54, 380-381.	0.9	0
600	Editorial Comment on: Cytological Punctures in the Diagnosis of Renal Tumours: A Study on Accuracy and Reproducibility. <i>European Urology</i> , 2009, 55, 197-198.	0.9	0
601	Editorial Comment on: Platelet Microparticles: A Potential Predictive Factor of Survival in Hormone-Refractory Prostate Cancer Patients Treated with Docetaxel-Based Chemotherapy. <i>European Urology</i> , 2009, 56, 484-485.	0.9	0
602	Editorial Comment. <i>Journal of Urology</i> , 2011, 186, 2199-2200.	0.2	0
603	Reply to Kiril Trpkov, Asli Yilmaz™ Letter to the Editor re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Original Gleason System Versus 2005 ISUP Modified Gleason System: The Importance of Indicating Which System Is Used in the Patient™s Pathology and Clinical Reports. <i>Eur Urol</i> 2010;58:369-73. <i>European Urology</i> , 2011, 59, e7-e8.	0.9	0
604	Genitourinary Tumor Pathology: Introductory Comments. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 357-359.	1.2	0
605	Reply to JÃ©rÃ©me Verine's Letter to the Editor re: Rodolfo Montironi, Antonio Lopez-Beltran, Liang Cheng, Marina Scarpelli. Re: Multilocular Cystic Renal Cell Carcinoma with Focus on Clinical and Pathobiological Aspects. <i>Eur Urol</i> 2013;63:400-1. <i>European Urology</i> , 2013, 63, e74-e75.	0.9	0
606	Reply to JÃ©rÃ©me Verine's Letter to the Editor re: Rodolfo Montironi, Marina Scarpelli, Liang Cheng, et al. Immunoglobulin G4-related Disease in Genitourinary Organs: An Emerging Fibroinflammatory Entity Often Misdiagnosed Preoperatively as Cancer. <i>Eur Urol</i> . In press. <a href="http://dx.doi.org/10.1016/j.eururo.2012.11.056">http://dx.doi.org/10.1016/j.eururo.2012.11.056</a> . <i>European Urology</i> , 2013, 64, e53-e54.	0.9	0
607	Prostate cancer grading in 2016. <i>Minerva Urology and Nephrology</i> , 2016, 69, 1-4.	1.3	0
608	Re: Idir Ouzaid and Karim Bensalah. Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE. <i>Eur Urol</i> 2015;68:542-3. <i>European Urology</i> , 2016, 70, e69-e70.	0.9	0
609	In reply to: letter to the editor entitled: primary pure lymphoepithelioma-like carcinoma of the ureter. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 561-562.	1.4	0
610	Re: A Novel Tool for Predicting Extracapsular Extension During Graded Partial Nerve Sparing in Radical Prostatectomy. <i>European Urology</i> , 2018, 73, 978-980.	0.9	0
611	Quick steps toward precision medicine in renal cell carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 283-285.	0.4	0
612	Editorial Comment. <i>Journal of Urology</i> , 2018, 199, 1486-1487.	0.2	0

#	ARTICLE	IF	CITATIONS
613	â™™,The Prostatic Utricle and Endometrioid Prostate Cancer. , 2019, , 123-127.		0
614	â™™,â™™€ Clear Cell Tumors of the Kidney and the Gynecologic Tract. , 2019, , 173-188.		0
615	Re: Lorenzo Marconi, Thomas Stonier, Rafael Tourinho-Barbosa, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. Eur Urol 2019;76:27â€“30. European Urology, 2020, 77, e100-e102.	0.9	0
616	Re: Maria Chiara Sighinolfi, Bernardo Roccoâ€™s Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. <a href="https://uroweb.org/guideline/prostate-cancer/">https://uroweb.org/guideline/prostate-cancer/</a> . Eur Urol 2019;76:871. European Urology, 2020, 77, e122-e127.	0.9	0
617	How radical prostatectomy procedures have changed over the last 10Âyears in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study. World Journal of Urology, 2021, 39, 1445-1452.	1.2	0
618	Let us not forget about our past contributions to the field of prostatic neoplasms: To some extent what we value now was already there. Pathology Research and Practice, 2021, 219, 153377.	1.0	0
619	The Wide Spectrum of Oncocytic Changes and Tumors in the Kidney: Splitting and Lumping. Pathobiology, 2021, 88, 1-4.	1.9	0
620	Conceptual Analogies Between Multi-Scale Feeding and Feedback Cycles in Supermassive Black Hole and Cancer Environments. Frontiers in Oncology, 2021, 11, 634818.	1.3	0
621	Re: Theo van der Kwast, Fredrik Liedberg, Peter C. Black, et al. International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. Eur Urol Focus. In press. <a href="https://doi.org/10.1016/j.euf.2021.03.017">https://doi.org/10.1016/j.euf.2021.03.017</a> . European Urology Focus, 2022, 8, 882-884.	1.6	0
622	RE: Noninvasive papillary urothelial neoplasia (NIPUN): Renaming cancer, by Jones TD and Cheng L, <a href="https://doi.org/10.1016/j.urolonc.2020.12.007">https://doi.org/10.1016/j.urolonc.2020.12.007</a> (Low grade papillary intra-urothelial neoplasia). Urologic Oncology: Seminars and Original Investigations, 2021, 39, 308-309.	0.8	0
623	Reply to Nicolas Mottet, Olivier Rouviere, and Theodorus H. van der Kwast. Incidental Prostate Cancer: A Real Need for Expansion in Guidelines? Eur Urol Oncol. In press. European Urology Oncology, 2021, 5, 261-261.	2.6	0
624	Re: If You Want to Make an Important Discovery, Listen to Your Patients. European Urology, 2021, 80, 672-673.	0.9	0
625	Re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. <a href="https://doi.org/10.1016/j.eururo.2021.03.009">https://doi.org/10.1016/j.eururo.2021.03.009</a> . European Urology, 2021, 80, e81-e82.	0.9	0
626	Whatâ€™s the future in uropathology. Urologia, 2021, 88, 265-266.	0.3	0
627	Role of Pathology in the Multidisciplinary Management of Patients with Prostate Cancer. , 2014, , 29-41.		0
628	Tumors and Tumor-Like Conditions of Urinary Bladder, Renal Pelvis, Ureter and Urethra. , 2015, , 63-194.		0
629	Pathologic Rationale for Focal Therapy of Prostate Cancer: Elucidating Tumor Characteristics and Biology. Current Clinical Urology, 2017, , 85-104.	0.0	0
630	Editorial on â€œAdjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trialâ€•. Translational Cancer Research, 2018, 7, S74-S76.	0.4	0

#	ARTICLE	IF	CITATIONS
631	Urothelial Carcinoma in Situ. Encyclopedia of Pathology, 2019, , 1-4.	0.0	0
632	Atypical Small Acinar Proliferation. Lecture Notes in Geoinformation and Cartography, 2019, , 1-3.	0.5	0
633	High-Grade Prostatic Intraepithelial Neoplasia. Encyclopedia of Pathology, 2019, , 1-3.	0.0	0
634	Inverted Urothelial Papilloma. Encyclopedia of Pathology, 2019, , 1-4.	0.0	0
635	Editorial Comment. Journal of Urology, 2019, 202, 715-716.	0.2	0
636	Staging and Reporting of Renal Cell Carcinomas. , 2020, , 423-436.		0
637	Specimen Handling: Radical and Partial Nephrectomy Specimens. , 2020, , 411-422.		0
638	Atypical Small Acinar Proliferation. Encyclopedia of Pathology, 2020, , 12-15.	0.0	0
639	The 1996 European Urology Focus on Preneoplastic Lesions of the Prostate. European Urology Focus, 2020, 7, 1504-1505.	1.6	0
640	High-Grade Prostatic Intraepithelial Neoplasia. Encyclopedia of Pathology, 2020, , 145-146.	0.0	0
641	Urothelial Carcinoma, Clear Cell (Glycogen-Rich) Type. Encyclopedia of Pathology, 2020, , 1-3.	0.0	0
642	Inverted Urothelial Papilloma. Encyclopedia of Pathology, 2020, , 158-161.	0.0	0
643	Pathology of the Benign and Malignant Diseases of the Prostate. , 2020, , 1-12.		0
644	Urothelial Carcinoma In Situ. Encyclopedia of Pathology, 2020, , 460-463.	0.0	0
645	Urothelial Carcinoma, Clear Cell (Glycogen-Rich) Type. Encyclopedia of Pathology, 2020, , 466-467.	0.0	0
646	Spectrum of incipient (or precursor) lesions in the mucosa of the seminal vesicles. Pathology Research and Practice, 2022, 229, 153737.	1.0	0
647	Classification and grading of noninvasive and invasive neoplasms of the urothelium. , 2012, 34, 111-9.		0